Composition comprising clay mineral complex for prevention, alleviation, and treatment of inflammatory bowel disease, preparation method for composition, and method for alleviation and treatment for inflammatory bowel disease
A clay mineral and a technology for a composition are applied in the field of a composition for preventing, improving and treating inflammatory colitis containing clay mineral complex, and the preparation of the composition and the improvement and treatment of inflammatory colitis, which can solve inflammation Problems such as irregular absorption of colitis compounds
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
preparation example Construction
[0043] And, the present invention relates to the preparation method of the pharmaceutical composition that is used for preventing and treating inflammatory colitis, comprises mixing the solution that comprises the compound of chemical formula 1 or its pharmaceutically acceptable salt, acidic reaction solution and clay mineral suspension and A step in which the above compound is adsorbed on clay minerals to prepare a composite.
[0044] Also, the present invention relates to a food composition for preventing and improving inflammatory colitis, the food composition comprising a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof and a complex of clay minerals.
[0045] Also, the present invention relates to a method for treating inflammatory colitis, comprising the step of administering a pharmaceutical composition to a subject, the pharmaceutical composition comprising a compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof and a c...
experiment example 1
[0090] 1-1
[0091] Evaluate the adsorption rate of vactosertib to bentonite according to the solvent pH. In this case, considering that vactosertib is not easily soluble in a neutral environment, it starts to dissolve at a solubility of about 1 mg / mL at pH 3. Therefore, the reaction pH values were selected as pH 1, pH 2 and pH 3 for testing.
[0092] First, dissolve vactosertib in 0.1N hydrochloric acid aqueous solution at a concentration of 10 mg / mL, and dilute it in hydrochloric acid aqueous solution or phosphate buffer solution corresponding to each pH value (pH1: 0.1N hydrochloric acid aqueous solution, pH2, pH3: phosphoric acid saline buffer) to a concentration of 1 mg / mL. Mix 1 mL of the relevant drug solution, 8 mL of the reaction solution corresponding to each pH value (i.e., 0.1 N hydrochloric acid aqueous solution or phosphate buffer) and 1 mL of a suspension prepared by suspending bentonite in distilled water to a concentration of 5 mg / mL Leave it for 30 minute...
experiment example 2
[0112] 2-1
[0113] The bentonite / vactosertib complex was prepared using the method of Experimental Example 1 under the conditions of 1 mg / ml vactosertib concentration and 5 mg / ml bentonite concentration using a pH 1 solvent. Then, after it was freeze-dried, in order to detect the actual content of vactosertib, the extraction and analysis of vactosertib were carried out.
[0114]The above freeze-dried complex was dispersed in phosphate buffered saline (phosphate buffered saline, pH 7.4) containing 0.5% Tween 80 to extract the results of vactosertib, the calculated reaction weight percentage of bentonite / vactosertib complex was The reaction weight percentage of the existing vactosertib and bentonite is approximately 16.9±0.2%. The reaction weight percentage is calculated by Mathematical Formula 2 below.
[0115] Mathematical formula 2
[0116]
[0117] 2-2
[0118] Evaluate the morphological properties of the bentonite / vactosertib complex prepared in 2-1 above. To this ...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More